Judge Pittman's Full Ruling in OFA v. FDA: The Legal Text That Reshaped Compounding

Judge Mark Pittman's ruling in the Outsourcing Facilities Association v. FDA cases became the pivot point for compounded GLP-1 legal ground. Here's what the ruling actually said, translated for patients rather than lawyers.

The Cases and the Court

The Outsourcing Facilities Association (OFA) filed suits against the FDA challenging the agency's authority to remove semaglutide and tirzepatide from official shortage lists. The shortage designation had been the legal basis under which compounding pharmacies produced the medications without violating "essentially copies" restrictions in Section 503A of the Federal Food, Drug, and Cosmetic Act.

Judge Mark Pittman of the Northern District of Texas heard the cases. His rulings on preliminary injunction motions were the pivot: denial of the PI meant FDA's shortage decisions stood while litigation proceeded, effectively closing the shortage-basis compounding pathway.

The Legal Reasoning

The court's reasoning applied standard preliminary injunction analysis: likelihood of success on the merits, irreparable harm, balance of equities, public interest. On the merits, the court gave substantial deference to the FDA's factual determinations about shortage status, applying the standard administrative-law framework for agency decisions.

On irreparable harm, the court accepted that OFA members faced business disruption but weighed that against FDA's public health interest in restricting compounded product where commercial supply had normalized. On balance of equities and public interest, the court favored allowing FDA's determination to stand.

What the Ruling Did and Didn't Do

The ruling did not declare compounded semaglutide or tirzepatide illegal per se. It allowed FDA's shortage-status decisions to stand, which closed the shortage-basis pathway. Compounding under alternative Section 503A bases — patient-specific personalization, alternative routes, combination products — remains legally viable.

The ruling also didn't foreclose appeal. The Fifth Circuit has been considering related issues, and further appellate developments could shift the ground again. Legal certainty in this area remains partial.

How the Industry Responded

Compounders responded by tightening intake documentation, emphasizing patient-specific personalization in prescriptions, and shifting some product lines (particularly oral formats and combination products) that have stronger regulatory footing. Some marketers wound down operations. The industry that persists is meaningfully different in intake structure and marketing language than the pre-ruling version.

The Ongoing Legal Landscape

Related litigation continues at multiple levels. State AG actions, individual company suits, and appellate developments are all active. Patients using compounded product should expect continued evolution — not necessarily dramatic disruption, but ongoing recalibration of what compounders can and can't market.

Where to Start